{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-052036","form_type":"8-K","ticker":"APUS","cik":"0001894525","company_name":"Apimeds Pharmaceuticals US, Inc.","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.250618+00:00","generated_at":"2026-05-14T23:34:22.606054+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Apimeds Pharmaceuticals appoints Sungjoon Chae as Co-CEO","bullets":["Sungjoon Chae appointed Co-CEO effective May 4, 2026, pursuant to a stockholder nomination.","No family relationships or related party transactions with company officers or directors.","Compensation terms for Chae have not yet been determined; will be disclosed when finalized.","Chae holds a Master of Architecture in Urban Design from Harvard University and specializes in large-scale real estate and urban regeneration.","Existing CEO Dr. Vin Menon continues as CEO; Chae serves as Co-CEO."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-052036","json":"https://secwatch.observer/filing/0001213900-26-052036.json","markdown":"https://secwatch.observer/filing/0001213900-26-052036.md","text":"https://secwatch.observer/filing/0001213900-26-052036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894525/000121390026052036/0001213900-26-052036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894525/000121390026052036/ea0289213-8k_apimeds.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:34:22.606054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c35bd825d7","claim":"Sungjoon Chae was appointed as Co-Chief Executive Officer at Apimeds Pharmaceuticals US, Inc..","evidence_excerpt":"On May 4, 2026, pursuant to a nomination by a stockholder of Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the \" Company \"), the board of directors of the Company (the \" Board \") appointed Sungjoon Chae to serve as Co-Chief Executive Officer of the Company, effective as of such date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1894525/000121390026052036/0001213900-26-052036-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Co-Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}